The fifth surfactant to be approved to treat Respiratory Distress Syndrome
(RDS) was approved by the FDA today. the new drug is called Surfaxin (lucinactant) and joins the 4 previously approved medicines for RDS. This drug was approved to prevent RDS based on one study of 1,294 premature infants. read the release at www.fda.gov.
Approval Date:
Tue, 03/06/2012
Company:
Discovery Laboratories, Inc.